Staff Writer - The Cancer News

The U.S. Food and Drug Administration approved Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy as the first line treatment for adults

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved Pembrolizumab (Keytruda) plus…

12 months ago

FDA Approves Nirogacestat for Adult Patients with Progressing Desmoid Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On the date of approval, the U.S. Food and Drug Administration approved Nirogacestat (Ogsiveo)…

12 months ago

Capivasertib Gets FDA Approval for Treatment of HR-Positive, HER2-Negative Breast Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved capivasertib (Truqap,…

12 months ago

FDA Grants accelerated approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma with Prior Therapy

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration granted accelerated approval for Pirtobrutinib (Jaypirca) to be…

12 months ago

PAPILLON: a randomized phase III study of amivantamab plus chemotherapy versus chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC)

By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In…

1 year ago

Staff Writer - The Cancer News

The U.S. Food and Drug Administration approved Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy as the first line treatment for adults

FDA Approves Nirogacestat for Adult Patients with Progressing Desmoid Tumors

Capivasertib Gets FDA Approval for Treatment of HR-Positive, HER2-Negative Breast Cancer

FDA Grants accelerated approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma with Prior Therapy

PAPILLON: a randomized phase III study of amivantamab plus chemotherapy versus chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC)

FDA Approves Toripalimab for Nasopharyngeal Carcinoma

Ivosidenib in Mutant IDH1 Relapsed/ Refractory Myelodysplastic Syndrome: Updated Substudy Results

FDA approves Pembrolizumab for resectable NSCLC in both neoadjuvant and adjuvant setting

Interview with Dr. Yinghong Wang on her book – Managing Immunotherapy Related Organ Toxicities: A Practical Guide.

Highlights from ESMO 2023: MARIPOSA-2